Dear Acting Commissioner Diamantas,

On November 19, 2026, STAT News reported that major pharmaceutical companies have told a House committee they will halt clinical trials at certain Chinese hospitals, citing data security risks, intellectual property exposure, and deepening geopolitical pressure from Congress. This is not a rumor circulating at a medical affairs offsite. This is an operational declaration, made in formal testimony before federal legislators. The sponsors who built multiregional trial strategies around Chinese enrollment capacity are now telling Congress those strategies are changing. And yet, as of today, your agency has published no guidance, no framework, and no formal advisory on what that change requires from a regulatory compliance standpoint.

That gap is what I want to talk to you about.

The Protocol Problem Congress Created Without Solving

When a large sponsor pulls clinical trial sites from Chinese hospitals mid-development, the downstream compliance consequences are significant. Protocols registered with pre-specified enrollment targets by geography now have holes in them. Statistical analysis plans built around patient populations from Chinese sites, where a Phase III oncology trial can cost an estimated $15 to $20 million compared to roughly $50 million in the United States, carry assumptions about disease prevalence, patient demographics, and standard-of-care comparators that may no longer hold when those sites go dark. Your own agency has flagged this risk in guidance on multiregional clinical trials in oncology, warning that when countries differ in disease characteristics, demographics, and standards of care, the generalizability of data across a trial’s population comes into question. Pulling Chinese sites doesn’t eliminate that concern. In many cases, it intensifies it, because sponsors now have to explain both the original inclusion of those sites and their subsequent removal.

The House committee heard the sponsors. What it did not produce is a regulatory roadmap. And in the absence of one from your agency, every sponsor currently managing an active IND with Chinese hospital sites is operating on improvised legal interpretations of existing protocol amendment procedures. That is not a sustainable posture for programs that may be three years from an NDA submission.

I recognize you stepped into this role at a moment of genuine institutional turbulence, with the Commissioner nomination process still unresolved and your agency managing a compressed leadership transition. You did not design this geopolitical environment. But the operational reality landing on sponsors’ desks right now is squarely within the FDA’s jurisdiction to address, and the absence of your agency’s voice is itself becoming a form of policy by default.

What the FDA’s Own Actions Already Signal

Your agency moved decisively in one direction already. On June 18, 2025, the FDA announced an immediate review of new clinical trials involving the export of American patients’ living cells to China and other designated hostile countries for genetic engineering and re-infusion. That action was targeted, it was swift, and it communicated a clear risk assessment to the field. Sponsors building CAR-T and cell therapy programs received a clear regulatory signal about the agency’s risk assessment. That precedent matters, because it demonstrates the agency can move quickly when the geopolitical risk is specific enough to name.

The problem is that the current wave of China trial withdrawals covers a much broader category than cell export. It covers conventional oncology MRCTs, cardiovascular endpoints studies, rare disease programs that have enrolled Chinese patients, and biologics trials where Chinese hospitals provided a substantial share of total enrollment. The June 2025 cell therapy action doesn’t speak to those programs, and sponsors know it. What they’re doing right now, absent clearer direction, is drafting protocol amendments that try to anticipate what a future FDA reviewer will accept as an adequate explanation for site removal. They’re guessing. And guesses made under geopolitical pressure, with legal counsel involved and a congressional committee watching, tend to produce conservative, enrollment-shrinking decisions that delay development timelines for patients everywhere.

The House Appropriations Committee’s FY2027 FDA funding bill has already included language aimed at restricting certain China-linked pharmaceutical development activities. Congress is building policy faster than your agency is interpreting it. That imbalance will cost sponsors months, possibly years, in development time, and it will cost patients access to therapies that stall in protocol limbo.

A Specific Ask, Not a General Concern

Here is where I think you can act, and act in a way that serves both regulatory integrity and sponsor practicality. I am asking you to issue, before the end of Q1 2027, a formal guidance document or at minimum a written Q&A product that addresses three specific operational questions every affected sponsor is currently wrestling with. First: when a sponsor removes Chinese hospital sites from an active IND due to geopolitical or data security considerations, what constitutes an adequate protocol amendment justification, and does that removal trigger a requirement for interim analysis of data already collected at those sites? Second: when Chinese site enrollment was material to a trial’s pre-specified statistical power, what is the agency’s expectation for re-powering the study from alternative geographies, and will the agency accept bridging data from those replacement sites? Third: for programs where Chinese patient data has already been incorporated into an ongoing trial’s dataset, what data integrity standards and documentation does the agency require to demonstrate that data was not subject to unauthorized access or export?

These are not abstract policy questions. They are the questions sitting in the inboxes of clinical operations teams at Pfizer, AstraZeneca, Roche, and every mid-sized oncology sponsor managing a multiregional program right now. Your agency’s China counterpart, the National Medical Products Administration, updated its own clinical trial guidelines to align more closely with ICH standards precisely to attract global sponsors. The environment your sponsors are navigating has two sets of regulatory expectations pulling in opposite directions. You can resolve at least the FDA side of that tension with a document that takes fewer weeks to draft than the protocol amendments sponsors are currently improvising.

I understand the institutional pressure you’re managing. A provisional title, a congressional hearing cycle focused on biosecurity, and an agency workforce navigating an ongoing leadership transition: none of that makes this easier. But the sponsors appearing before that House committee aren’t signaling a theoretical future shift. They’ve made the decision. The China hospital sites are coming offline. While existing GCP frameworks and FDA guidance address individual subject withdrawals and data retention, no consistent, prospective regulatory standard governs how the agency will adjudicate submissions from trials disrupted by large-scale or policy-driven withdrawal events, leaving those decisions potentially inconsistent across reviewers and submissions. The first approach protects patients. The second one protects nobody.

The next sponsor to submit a protocol amendment explaining why their Chinese sites went dark will be testing whatever informal standard your reviewers have developed on their own. Issue the guidance before that submission becomes the precedent.

With concern,

Moe Alsumidaie
Editor-in-Chief, Clinical Trial Vanguard

References

  1. STAT News, “Big drugmakers tell House committee they will halt clinical trials at some hospitals in China” (November 19, 2026)
  2. FDA, “FDA Halts New Clinical Trials That Export Americans’ Cells to Foreign Labs in Hostile Countries for Genetic Engineering” (June 18, 2025)
  3. Leon Liao, “Who Controls the Geography of Global Oncology Trials?”, FDA multiregional clinical trial enrollment and demographic generalizability concerns
  4. Endpoints News, Congressional Biotech Commission warns on China deal flow; House Appropriations FY2027 FDA bill language on China pharmaceutical development
  5. Vision Life Sciences, China Phase III oncology trial cost estimates ($15–20 million vs. ~$50 million in the United States)
  6. Cure4Cancer Global, China NMPA modernized clinical trial guidelines aligned with ICH standards
Website | + posts

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.